Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

870 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: langer c. J Natl Cancer Inst. 2015 Feb 24;107(3):dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25713148 Free PMC article.
Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Lurje G, et al. Among authors: langer c. Clin Cancer Res. 2008 Dec 1;14(23):7884-95. doi: 10.1158/1078-0432.CCR-07-5165. Clin Cancer Res. 2008. PMID: 19047118
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, LaBonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Zhang W, et al. Among authors: langer c. Ann Oncol. 2011 Jan;22(1):104-109. doi: 10.1093/annonc/mdq315. Epub 2010 Jul 5. Ann Oncol. 2011. PMID: 20603437 Free PMC article. Clinical Trial.
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. Sobrero AF, et al. Among authors: langer c. J Clin Oncol. 2008 May 10;26(14):2311-9. doi: 10.1200/JCO.2007.13.1193. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390971 Clinical Trial.
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RP, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S. Jonker DJ, et al. Among authors: langer c. Br J Cancer. 2014 Feb 4;110(3):648-55. doi: 10.1038/bjc.2013.753. Epub 2013 Dec 12. Br J Cancer. 2014. PMID: 24335920 Free PMC article.
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM, Herzog C, Whitlock JA, Wolff J, Kuttesch J, Bagatell R, Hunger SP, Boklan J, Smith AA, Arceci RJ, Katzenstein HM, Harbison C, Zhou X, Lu H, Langer C, Weber M, Gore L. Trippett TM, et al. Among authors: langer c. J Clin Oncol. 2009 Oct 20;27(30):5102-8. doi: 10.1200/JCO.2008.20.8975. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770383 Free PMC article. Clinical Trial.
Cetuximab for the treatment of colorectal cancer.
Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Jonker DJ, et al. Among authors: langer c. N Engl J Med. 2007 Nov 15;357(20):2040-8. doi: 10.1056/NEJMoa071834. N Engl J Med. 2007. PMID: 18003960 Free article. Clinical Trial.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. Karapetis CS, et al. Among authors: langer c. N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385. N Engl J Med. 2008. PMID: 18946061 Free article. Clinical Trial.
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
870 results